SYRE SEC Form 4 filings
Spyre Therapeutics, Inc. Latest Insider Trading Activity
The most recent employee insider trading activity for Spyre Therapeutics, Inc. reports 4 sales by King-Jones Heidy (Spyre Therapeutics, Inc. Officer) totaling 27,999 shares at a weighted-average price of $87.32 per share, with the latest transaction dated September 2, 2026. For the past 68 days, SYRE has had 27 total insider transactions represented in the displayed records. This page shows up to the 10 most recent SEC Form 4 filing records on a 24-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.
⚠️ THE SAMPLE BELOW IS DEFERRED BY 24 HOURS ⚠️
Start your 2-week, no-credit-card free trial today to receive get down to the second insider trading updates in this directory or email.
| Ticker | Filing Date | Transaction Date | Company | Insider | Title | Transaction | Trade Count | Shares | Avg. Price | Total Value | Position Size Change | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SYRE | 2026-09-03 | 2026-09-01 | Spyre Therapeutics, Inc. | King-Jones Heidy | Officer | Sell | 1 | 400 | $89.38 | $35,752.00 | 12.33% | View Filing |
| SYRE | 2026-09-03 | 2026-09-02 | Spyre Therapeutics, Inc. | King-Jones Heidy | Officer | Sell | 4 | 27,999 | $87.32 | $2,444,776.62 | 40.26% | View Filing |
| SYRE | 2026-09-03 | 2026-09-01 | Spyre Therapeutics, Inc. | Burrows Scott L | Chief Financial Officer | Sell | 4 | 7,500 | $87.31 | $654,791.72 | 1.84% | View Filing |
| SYRE | 2026-09-03 | 2026-09-02 | Spyre Therapeutics, Inc. | Burrows Scott L | Chief Financial Officer | Sell | 1 | 18,232 | $89.35 | $1,629,029.20 | 18.61% | View Filing |
| SYRE | 2026-09-03 | 2026-09-01 | Spyre Therapeutics, Inc. | Turtle Cameron | Chief Executive Officer | Sell | 4 | 15,000 | $87.29 | $1,309,410.00 | 0.67% | View Filing |
| SYRE | 2026-08-10 | 2026-08-07 | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Director | Sell | 2 | 18,000 | $104.55 | $1,881,840.00 | 38.53% | View Filing |
| SYRE | 2026-08-10 | 2026-08-07 | Spyre Therapeutics, Inc. | Albers Jeffrey W. | Director | Sell | 1 | 5,000 | $104.47 | $522,350.00 | 100.00% | View Filing |
| SYRE | 2026-08-05 | 2026-08-03 | Spyre Therapeutics, Inc. | Burrows Scott L | Chief Financial Officer | Sell | 3 | 7,500 | $95.57 | $716,771.00 | 2.47% | View Filing |
| SYRE | 2026-08-05 | 2026-08-03 | Spyre Therapeutics, Inc. | Turtle Cameron | Chief Executive Officer | Sell | 5 | 15,000 | $95.51 | $1,432,705.05 | 0.52% | View Filing |
| SYRE | 2026-07-02 | 2026-07-01 | Spyre Therapeutics, Inc. | Burrows Scott L | Chief Financial Officer | Sell | 2 | 7,500 | $87.74 | $658,039.50 | 3.65% | View Filing |
Real-time employee trading alerts from SEC Form 4 filings. Sign up for a free trial. No credit card required.
Pricing
Free Trial
10 trading daysExplore every Premium feature before you pay.
- Full platform access
- 10 trading days
- No credit card required
- 20 years of alert history
- Live alert directory updates
Standard Monthly
ScheduledScheduled alerts with complete trade context.
- Email and Telegram delivery
- Alert intervals from every sixty minutes to once daily
- Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
- Highlighted cluster transactions and SEC filing links
- Access to the alert directory hourly refreshes
Premium Monthly
RecommendedFastest alerts with ticker-level control.
- Everything in Standard
- Instant delivery detection-to-outbound time averages 0.85 seconds
- Alert intervals starting from one minute
- Real time alert directory updates